EUVIMEDEUVIMED entdecken
Crossref

Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study

Douglas Tremblay, Abiola Oladapo, Emily Levine, Michael Marrone, Djibril Liassou, Purvi Suthar, Adina Geprifti, Gerard Hoehn, Michael Vredenburg, Bruce Feinberg, Naveen Pemmaraju, James Rossetti

NCODA Oncology and Hematology Meeting Abstracts · 2026

DOI: 10.67209/wpqr5260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, 2026. Verfasst von Douglas Tremblay und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: Sobi Inc..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pacritinib (PAC), a JAK1 sparing JAK2/IRAK1/ ACVR1 inhibitor is approved for patients with myelofibrosis (MF) and severe thrombocytopenia (platelet [PLT] counts

Förderung

  • Sobi Inc.

Zitieren

APA

Tremblay, D., Oladapo, A., Levine, E., Marrone, M., Liassou, D., Suthar, P., Geprifti, A., Hoehn, G., Vredenburg, M., Feinberg, B., Pemmaraju, N., & Rossetti, J. (2026). Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/wpqr5260

Vancouver

Tremblay D, Oladapo A, Levine E, Marrone M, Liassou D, Suthar P, et al. Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/wpqr5260

BibTeX
@article{Tremblay2026,
  author = {Tremblay, Douglas and Oladapo, Abiola and Levine, Emily and Marrone, Michael and Liassou, Djibril and Suthar, Purvi and Geprifti, Adina and Hoehn, Gerard and Vredenburg, Michael and Feinberg, Bruce and Pemmaraju, Naveen and Rossetti, James},
  title = {Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  doi = {10.67209/wpqr5260}
}
Kostenlos starten →